España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Poniard Pharmaceuticals
PARD
OTCEM
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.000100
Last update: Dec 31, 7:00 PM
Get Report
Comment
Poniard Pharmaceuticals (PARD) Forecast
News
Earnings
Poniard Pharmaceuticals (PARD) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Poniard Pharmaceuticals (OTC:PARD) Stock
Poniard Pharmaceuticals Stock (OTC: PARD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 03, 2012
UPDATE: Poniard Pharmaceuticals Common Stock to Be Delisted From Nasdaq Stock Market, Intention to List on OTC Bulletin Board
Benzinga
Friday, December 30, 2011
Poniard Pharmaceuticals Delisting to Pink She...
Benzinga
Saturday, November 19, 2011
Microcap Movers For Friday November 18, 2011
Benzinga
Friday, November 18, 2011
Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology
Benzinga
Wednesday, November 09, 2011
ISS Proxy Advisory Services Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split
Benzinga
Monday, November 07, 2011
Glass Lewis Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split
Benzinga
Friday, October 28, 2011
Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split
Benzinga
Tuesday, September 06, 2011
Poniard Pharmaceuticals Receives Favorable NASDAQ Decision for Continued Listing of Company Shares
Benzinga
Poniard Pharmaceuticals Receives Favorable NASDAQ Decision for Continued Listing of Company Shares
Benzinga
Monday, July 25, 2011
Poniard May be Delisted by NASDAQ
Benzinga
Monday, July 11, 2011
Poniard Pharmaceuticals Adjourns Reconvened Annual Meeting of Shareholders to Solicit Additional Proxies for Important Reverse Stock Split Proposal
Benzinga
Tuesday, July 05, 2011
Poniard Pharmaceuticals Announces Intention to Adjourn Annual Meeting of Shareholders to Solicit Additional Proxies for Reverse Stock Split Proposal
Benzinga
Wednesday, June 22, 2011
Poniard Pharmaceuticals Surges On Merger News With Allozyne
Benzinga
UPDATE: Poniard Pharmaceuticals Resumes Tradi...
Benzinga
UPDATE: Poniard Pharmaceuticals Resumes Tradi...
Benzinga
Poniard Pharmaceuticals and ALLOZYNE Sign Definitive Merger Agreement
Benzinga
Poniard Pharmaceuticals Halted, Pending News
Benzinga
Tuesday, May 31, 2011
Poniard Pharmaceuticals Board of Directors Urges Shareholders to Vote FOR Reverse Stock Split Proposal
Benzinga
Poniard Says 2 Proxy Firms Recommend Vote For...
Benzinga
Wednesday, March 30, 2011
Poniard Pharma Beats EPS By $0.02 (PARD)
Benzinga
Poniard Pharmaceuticals Reports Q4 EPS $(0.11)
Benzinga
Thursday, January 20, 2011
PARD And MOBI Hitting Intra-Day Highs
Benzinga
Tuesday, December 21, 2010
Small Biotechnology Hot, Is Labopharm Next?
Benzinga
Thursday, December 16, 2010
Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan
Benzinga
Wednesday, December 08, 2010
Biotechnology Stocks Hot Off Of Orexigen Panel Vote
Benzinga
Tuesday, November 09, 2010
Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results: Loss Per Share of $0.13
Benzinga
Monday, March 22, 2010
How Will Obama-Care Play Into The Markets And ETFs?
Benzinga
Monday, January 25, 2010
Feuerstein Sees PARD as Case of “Sell On News”
Benzinga
Benzinga’s Top Downgrades (STP, STJ, GPC, PARD)
Benzinga
Benzinga’s Top Pre-Market Losers (PARD, DLTR, GENZ, SNDA, ACOR, TTHI, HCBK)
Benzinga
Friday, January 08, 2010
Top 5 Most Advanced NASDAQ Stocks (ZUMZ, INSP, SHLD, HRTN, PARD)
Benzinga
Thursday, December 03, 2009
Interesting Trade in Poniard
Benzinga
Wednesday, November 18, 2009
Benzinga’s Top Pre- Market Gainers (VVUS, PARD, CSUN, SOLF, NLST, ASMI, CAKE)
Benzinga
Monday, November 16, 2009
Biggest Losers (CAEI, TBV, PARD, CRXX, HOOK, ADY)
Benzinga
Benzinga’s Top Pre- Market Losers (CADC, TIBX, PARD, HGSI, SHPGY, ATVI)
Benzinga
Poniard Pharmaceuticals Shares Slammed
Benzinga
Poniard Pharmaceuticals Announces Pivotal Phase 3 of Picoplatin Did Not Meet Primary Endpoint
Benzinga
Friday, November 13, 2009
Poniard Pharmaceuticals Inc (NASDAQ:PARD) Highest Implied Volatility
Benzinga
